Drug intelligence / Profile preview

MNI-1038

Development stage: Preclinical
Lead developer: Invicro
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

MNI-1038 is a fluorine-18 labeled positron emission tomography (PET) radiotracer that targets synaptic vesicle glycoprotein 2A (SV2A). It is the racemic mixture of SynVesT-1 (also known as MNI-1126 or SDM-8). Developed by Invicro (formerly Molecular NeuroImaging), MNI-1038 is used as an in vivo diagnostic imaging agent to measure and monitor synaptic density and synaptic loss in neurodegenerative and neuropsychiatric disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, and cortical dysplasia.

Other names: 4-(3,5-difluorophenyl)-1-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one[18F]MNI-1038fluorine-18 MNI-1038fluorine18 MNI-1038fluorine 18 MNI-1038racemic SDM-8racemic SynVesT-1

Targets

SV2A (Synaptic vesicle glycoprotein 2A)

Beyond the preview

Go deeper on MNI-1038.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MNI-1038.